Loading
A phase 2 trial of Disitamab vedotin, Toripalimab, Epirubicin and Cyclophosphamide in HER2-positive breast cancer and HR-positive / HER2-negative breast cancer, run by RemeGen Co., Ltd., now recruiting.
To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer is a phase 2 interventional study registered as NCT06389006 by RemeGen Co., Ltd., with 79 participants planned, started 2024-04-29 and due to reach its primary completion in 2025-06-01. Interventions recorded: Disitamab Vedotin for Injection, Toripalimab, Epirubicin and Cyclophosphamide.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares RemeGen, Disitamab vedotin, Epirubicin, Toripalimab and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Toripalimab, HER2-positive breast cancer and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Toripalimab, HER2-positive breast cancer and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Toripalimab, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares RemeGen, Disitamab vedotin, HER2-positive breast cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Epirubicin, High-risk early HR-positive breast cancer, Cyclophosphamide, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Antibody-drug conjugate (ADC), Immune checkpoint inhibitors and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Antibody-drug conjugate (ADC) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/